BIO News and Press, Bio-Rad Laboratories Inc. Class A From 12/15/22

Olympus Named to Dow Jones Sustainability World Index for Two Consecutive Years TOKYO, Dec 16, 2022 - (JCN Newswire) - Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer and more fulfilling, announced that it has been selected...

Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases TOKYO, Dec 15, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai and Washington Un...

Data Shows 50% of New Trials Have Sites in Asia Pacific SYDNEY, AU, Dec 15, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pa...

Polymer protection for vaccines and drugs TSUKUBA, Japan, Dec 9, 2022 - (ACN Newswire) - A biocompatible polymer could help deliver vaccines and drugs with reduced risk of the rare dangerous adverse reaction called anaphylaxis. Researchers at the National Institute of Advanced Indus...

Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing SINGAPORE, Dec 6, 2022 - (ACN Newswire) - Leading pharma companies GSK, Sanofi and Takeda will partner with research communities from the Agency for Science, Technology and...

Olympus Announces Launch of Olympus Asia Pacific Innovation Program SINGAPORE, Dec 5, 2022 - (JCN Newswire) - Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer and more fulfilling, has partnered with MedTech Innovator Asia Pa...

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium TOKYO, Dec 1, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HA...

Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference TOKYO, Nov 30, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai...

Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine TOKYO, Nov 30, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Bioge...

Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies TOKYO, Nov 29, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced that its application for a partial change to label for Aricept (donepezil hy...